Company intelligence / Profile preview
SCG Cell Therapy
Singapore, Singaporescgcell.com ↗
- Ownership
- Private
- Employees
- ~200
- Development stage
- Phase 1
01
Overview
SCG101, their lead autologous HBsAg-specific TCR-T cell therapy, showed 100% HBsAg+ hepatocyte eradication and 74.5% HCC tumor reduction with a single dose in clinical trials. The therapy has received approvals from FDA, NMPA, and HSA for clinical trials in patients with HBV-related HCC.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- T cell therapiesbispecific antibodiestherapeutic vaccinesRNA-based therapeutics
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Singapore Health Sciences Authority (HSA)Agency for Science, Technology and Research (A*STAR)Advanced Cell Therapy and Research Institute SingaporeA*STAR's Bioprocessing Technology InstituteInstitute of Molecular and Cell Biology
Beyond the preview
Go deeper on SCG Cell Therapy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SCG Cell Therapy.